Schachter J, West S K, Mabey D, Dawson C R, Bobo L, Bailey R, Vitale S, Quinn T C, Sheta A, Sallam S, Mkocha H, Mabey D, Faal H
Department of Laboratory Medicine, University of California, San Francisco 94143-0842, USA.
Lancet. 1999 Aug 21;354(9179):630-5. doi: 10.1016/S0140-6736(98)12387-5.
Trachoma is the leading cause of preventable blindness. Programmes to prevent blindness due to trachoma are based on community-wide treatment with topical tetracycline. We assessed the potential of community-wide azithromycin treatment for trachoma control.
Pairs of villages in trachoma endemic areas of Egypt, The Gambia, and Tanzania were matched on trachoma rates in 1-10-year-old children. Villages were randomly assigned community-wide oral azithromycin treatment (three doses with intervals of 1 week) or treatment with 1% topical tetracycline (once daily for 6 weeks). Clinical examinations were done at baseline, 2-4.5 months, and 12-14 months after treatment. Chlamydia trachomatitis was identified by ligase chain reaction (LCR). Analyses were by intention to treat. Univariate comparisons and multivariate analyses were used to compare outcomes.
LCR positivity was correlated with clinical severity, but about 30% of Egyptian and Gambian villagers with no active disease were LCR positive. Village-wide LCR positivity ranged from 16.5% (Tanzania) to 43.6% (Egypt). Treatment compliance was over 90% except in the tetracycline treatment village in Egypt. Of the participants initially LCR positive, 866 (95%) of 924 who received at least one azithromycin dose and 482 (82%) of 587 who received 28 days or more topical tetracycline, were negative at follow-up. At 1 year, village-wide LCR positivity rates were substantially lower than at baseline with both treatments; the decreases were greater with azithromycin than with tetracycline (93% vs 77% in Egypt, 78 vs 66% in The Gambia, 64 vs 55% in Tanzania). Similarly, greater reduction in clinical activity occurred after azithromycin. In multivariate analyses, factors associated with being LCR positive at 1 year were: not receiving azithromycin; age under 10 years; and LCR positivity at baseline.
Community-wide treatment with oral azithromycin markedly reduces C. trachomatis infection and clinical trachoma in endemic areas and may be an important approach to control of trachoma.
沙眼是可预防失明的主要原因。预防沙眼致盲的项目基于社区范围内使用局部四环素进行治疗。我们评估了社区范围内使用阿奇霉素治疗控制沙眼的潜力。
在埃及、冈比亚和坦桑尼亚沙眼流行地区,将成对的村庄按照1至10岁儿童的沙眼发病率进行匹配。村庄被随机分配接受社区范围内的口服阿奇霉素治疗(分三剂,间隔1周)或1%局部四环素治疗(每日一次,持续6周)。在基线、治疗后2至4.5个月以及12至14个月进行临床检查。通过连接酶链反应(LCR)鉴定沙眼衣原体。分析采用意向性分析。单变量比较和多变量分析用于比较结果。
LCR阳性与临床严重程度相关,但约30%没有活动性疾病的埃及和冈比亚村民LCR呈阳性。全村LCR阳性率从16.5%(坦桑尼亚)到43.6%(埃及)不等。除埃及四环素治疗村外,治疗依从性超过90%。在最初LCR呈阳性的参与者中,接受至少一剂阿奇霉素的924人中有866人(95%)以及接受28天或更长时间局部四环素治疗的587人中有482人(82%)在随访时呈阴性。在1年时,两种治疗方法下全村LCR阳性率均显著低于基线水平;阿奇霉素治疗的下降幅度大于四环素治疗(埃及为93%对77%,冈比亚为78%对66%,坦桑尼亚为64%对55%)。同样,阿奇霉素治疗后临床活动性的降低幅度更大。在多变量分析中,与1年时LCR呈阳性相关的因素为:未接受阿奇霉素治疗;年龄在10岁以下;以及基线时LCR呈阳性。
社区范围内口服阿奇霉素治疗可显著降低流行地区沙眼衣原体感染和临床沙眼,可能是控制沙眼的重要方法。